Efficacy and safety of anlotinib in combination with immune checkpoint inhibitors or not as advanced non-small cell lung cancer treatment: a systematic review and network meta-analysis.

Transl Cancer Res · 2024 · PMC11170544 · PMID 38881944

Europe PMC DOI

hedged sentence

—

closest p

—

boldest claim

The sentences

marginally significantno p-value reported

For OS, anlotinib plus ICIs demonstrated marginally significant improvement versus anlotinib (HR =0.79, 95% CI: 0.54, 1.01) and versus ICIs (HR =0.72, 95% CI: 0.47, 1.01).

also in 26,082 other papers

Quoted from the open-access full text in Europe PMC under the licence the publisher applied. The sentence is reproduced exactly as published; the emphasis is ours.